A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
List view / Grid view
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
A team has shown that the NapA protein, associated with Lyme disease, attracts inflammatory molecules in the body.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
A new study has identified a key molecule involved in Lyme arthritis which presents options for preventative therapies.